Proteins may be therapeutic targets for TKI-resistant CML, ALL

Micrograph showing TKI-
resistant CML in a mouse
Photo courtesy of
Cincinnati Children’s
Hospital Medical Center
Researchers say they have identified 2 signaling proteins that enable resistance to tyrosine kinase inhibitors (TKIs) and could be therapeutic targets for acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML). The team found that by... [Read Article]

MRD predicts outcome of HSCT in ALL, study suggests

HSCT preparation
Photo by Chad McNeeley
Minimal residual disease (MRD) measurements before and after hematopoietic stem cell transplant (HSCT) can help predict outcomes in patients with childhood acute lymphoblastic leukemia (ALL), according to researchers. Their work also suggests several other factors can be used to predict event-free survival (EFS) in this patient population,... [Read Article]

Genetic variants linked to HSCT outcomes in ALL

Genome analysis
Image courtesy of the
National Institute of
General Medical Sciences
Results of a genome-wide association study suggest that several genetic variants are associated with outcomes of allogeneic hematopoietic stem cell transplant (HSCT) in patients with acute lymphoblastic leukemia (ALL). Investigators identified several single-nucleotide polymorphisms (SNPs) in ALL patients and their unrelated... [Read Article]

Blinatumomab bests chemo in rel/ref B-ALL

Vials of blinatumomab powder and solution for infusion
Photo courtesy of Amgen
Blinatumomab proved more effective than chemotherapy in a phase 3 trial of adults with Ph-negative, relapsed/refractory B-cell precursor acute lymphoblastic leukemia (B-ALL). Blinatumomab produced higher remission rates and nearly doubled overall survival (OS) when compared to standard care, which encompassed 4... [Read Article]

FDA grants priority review to ALL drug

B-cell precursor ALL
The US Food and Drug Administration (FDA) has granted priority review for inotuzumab ozogamicin as a treatment for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The FDA grants priority review to applications for products that may provide significant improvements in the treatment, diagnosis, or prevention of serious conditions.... [Read Article]